The Biosimilar Marketing Challenge: Building Confidence in a New Category

Biosimilars have FDA approval, solid data, and lower costs, but adoption lags. Prescribers hesitate, and patients worry about safety. Payers push biosimilar use, yet many doctors remain cautious. The main challenge is confidence, not science. To build the market, marketing must target both psychology and product performance, especially since trust defaults to the original biologic.

Why Biosimilar Marketing Requires a Different Approach Than Traditional Drug Marketing

Most pharmaceutical marketing builds awareness for a new product without direct competition. Biosimilars are different: the original biologic has earned physician loyalty and is already familiar to patients. A biosimilar must challenge an established, trusted product.

This changes the marketing goal from just building awareness to helping people adjust their thinking. Marketers must show clinical equivalence to prescribers, payers, and patients without making their past choices seem mistaken. This subtle challenge is often overlooked.

Generic drug marketing is sometimes compared to biosimilar marketing, but the comparison is limited. Generics are chemically identical to their reference products.

Biosimilars are highly similar, not identical, to their reference biologic because biologics are large, complex molecules derived from living cells. The FDA’s 351(k) regulatory pathway accounts for this complexity and requires thorough analytical studies, preclinical data, and clinical evidence before a biosimilar can be approved.

Still, “highly similar” leaves room for doubt in a prescriber’s mind, and that doubt is where biosimilar marketing must do its heaviest work.

Most biosimilar brands enter the market with strong data and weak storytelling. Regulatory approval is earned. Confidence must be built through consistent, audience-specific communication that starts well before launch and continues long after. Start developing this trust-building strategy today—commit your resources to telling your biosimilar story.

The Three Audiences That Determine Biosimilar Adoption

Biosimilar marketing must build confidence across three groups with different concerns and trust criteria. Focusing on only one or two slows adoption, even for deserving products.

Here’s how each audience thinks about biosimilars:

• Prescribers and Physicians: Their primary concern is patient safety and ensuring clinical outcomes are as good as the reference biologic. They need peer-reviewed evidence, real-world data, and assurance that switching to a biosimilar will not disrupt stability. Preserving strong patient relationships is critical, and prescribers value clear, proactive information to address patient concerns quickly and confidently.
• Payers and Pharmacy Benefit Managers (PBMs): Payers prioritize cutting costs, maintaining formulary control, and ensuring effective use. They require convincing clinical proof to justify preferring biosimilars, especially to medical directors and plan sponsors. Their decisions hinge on robust data and clear communication that builds trust in biosimilar value for their organizations.
• Patients: Patients with autoimmune conditions, cancers, or chronic illnesses primarily seek stability and rely on their current biologic. Their need is reassurance—confidence that switching therapies will not compromise their health or well-being, and that any changes are made for their best interest, not just for cost reasons.

What Prescribers Need Before They Will Recommend a Biosimilar

Prescribers are open to biosimilars, especially for new patients. The challenge lies with those already stable on treatment; switching feels risky, despite low actual risk.

To build prescriber confidence, biosimilar marketing must answer the specific clinical and practical questions doctors have about switching.

The areas that most affect prescriber confidence:

• Immunogenicity data: Prescribers want assurance that the biosimilar has been well tested for immune response and that it compares well with the reference biologic. This source of hesitation is often under-addressed.
• Indication extrapolation: Many biosimilars carry indications that were not directly studied in clinical trials but are granted based on the science of similarity.
• Credible Explanations: Prescribers in these specialties need clear and credible explanations of why extrapolation is scientifically valid, not just official regulatory terms.
• Interchangeability designation: If a biosimilar receives this status from the FDA, it meets a higher standard and can be substituted by pharmacists without a new prescription. Highlighting this status shows a level of confidence that regular FDA approval does not.
• Real-world evidence (RWE): Post-marketing surveillance data and real-world outcomes from practices already using the biosimilar carry significant weight.
• Communication: Peer-to-peer communication and sharing real case studies are effective because doctors trust information from other clinicians more than from brands.
• Practical switching support: Prescribers want to know what help is available during transitions. Support might include monitoring tools, clinical education resources, and quick access to medical affairs contacts for questions.

“Physician education in biosimilar marketing works best when it speaks to clinical judgment, not just product features. Prescribers want to feel like experts in what they’re recommending. Give them the knowledge to own that conversation with their patients.” — Strategy Team, Emulent Marketing

How Payer Relationships and Formulary Placement Drive Market Access

Even if prescribers are willing and patients are open, market access barriers can still block biosimilar adoption.

Whether a biosimilar is affordable depends on its formulary placement. Payers and PBMs balance clinical evidence, cost savings, and administrative risks when making these decisions.

Focusing solely on price limits opportunities when marketing to payers.

Payers make formulary decisions within complex systems that include medical directors, pharmacy committees, and plan sponsor expectations. The clinical narrative matters as much as the rebate structure.

Key considerations for reaching payers effectively:

• Health economic data: Payers respond best to analyses showing cost savings at the plan level—not just per-unit cost.
• Modeling: Modeling includes projected savings from biosimilar uptake across covered lives, as well as any downstream costs, such as monitoring or adverse events.
• Step therapy and prior authorization management: Some payers use step-therapy protocols that can slow biosimilar uptake. These require patients to try specific products first.
• Clear positioning: Marketing should clearly articulate how formulary design affects patient outcomes and total cost of care.
• Specialty pharmacy relationships: Many biologic therapies and their biosimilar alternatives are dispensed through specialty pharmacies. These pharmacies have significant influence over dispensing decisions, and manufacturers who build strong relationships with them often see more prescriptions filled.
• Preferred formulary positioning: Getting a biosimilar on the preferred tier creates a financial incentive for patients and prescribers to choose it over the reference biologic. This is where payer and patient marketing overlap. Preferred placement is only effective if patients understand and accept the lower out-of-pocket costs.

Building Patient Confidence When a Switch Feels Uncertain

Many biosimilar marketing teams do not invest enough in building patient confidence, even though it often determines whether formulary placement or doctor recommendations drive real adoption.

Patient marketing should focus on reassurance. While cost matters, those with serious illnesses require trust in safety before accepting a new medication.

What patient confidence-building looks like in practice:

• Plain-language clinical education: Clearly explain what “highly similar” and “no clinically meaningful differences” mean for patients. Show how these terms affect their health choices. Making this clear should be a top priority in patient education.
• Regulatory language is not reassuring on its own: Marketing should translate that language into what it means for their daily treatment.
• Support programs during transition: Nurse hotlines, patient support coordinators, and access to medical affairs staff during a switch help reduce anxiety and build trust. These programs also provide real-world stories and data for future marketing. Build or enhance your patient support resources now to boost adoption and trust.
• Patient advocacy organization partnerships: Organizations focused on conditions such as rheumatoid arthritis, inflammatory bowel disease, or oncology have built patient trust. Partnering with them to distribute educational materials gives biosimilar messaging a level of credibility that brand-owned communications struggle to match.
• Cost and access messaging as a secondary layer: Once a patient feels clinically confident, the financial benefit becomes a meaningful added reason to switch. Lead with clinical confidence, then reinforce with access and affordability messaging.

“Patients don’t need to understand the science of biosimilar development. They need to understand that their treatment is safe, that their doctor supports the change, and that someone is available if they have concerns. That’s the marketing work that actually moves patient adoption.” — Strategy Team, Emulent Marketing.

What a Confidence-Building Biosimilar Campaign Looks Like in Practice

A biosimilar campaign that builds confidence across all three audiences works as one coordinated strategy, not three separate ones. Each message supports the next: prescriber confidence helps patient conversations, payer access lowers financial barriers, and patient acceptance supports the prescriber’s choice.

The components that strong biosimilar campaigns share:

• Pre-launch scientific exchange: Medical affairs and marketing teams should work together before launch to start clinical conversations with prescribers through advisory boards, conferences, and peer-to-peer programs. This builds awareness in clinical networks before the main marketing begins.
• Clear, consistent positioning on similarity and approval: All materials for different audiences should repeat the same main message about the FDA approval process and the data supporting the biosimilar. If the science is explained inconsistently, it creates doubt instead of confidence.
• Segmented digital content by audience: The website for prescribers, the evidence dossier for payers, and support resources for patients each serve different needs. Using the same content for all three weakens the message. Tailored digital content for each audience works much better.
• Ongoing RWE communication: Real-world evidence collected after launch should be added to marketing materials. Data from post-marketing surveillance, patient registries, and published results from practices using the biosimilar all help build a stronger case over time.
• Sales force readiness: The field team brings the message directly to prescribers. They need solid training on clinical objections, not just product details. The most common questions from prescribers should have clear, confident answers backed by clinical references that reps can share.

“Biosimilar confidence isn’t built in a single campaign. It’s built through sustained, credible communication that compounds over the first two to three years in market. The brands that invest in that long game are the ones that earn lasting market share.” — Strategy Team, Emulent Marketing.

How the Emulent Marketing Team Can Help With Your Biosimilar Marketing Strategy

Building confidence in biosimilars takes more than just a launch plan. It needs a coordinated strategy that reaches prescribers, payers, and patients with the right message at the right time. This strategy should be based on clinical credibility and a clear understanding of what each audience needs to feel secure. That’s the kind of work we specialize in.

We partner with pharmaceutical and healthcare marketing teams to create content strategies, medical education programs, and digital campaigns that build trust in the biosimilar category over time. If you are planning a biosimilar launch or want to improve the adoption of an existing product, reach out to the Emulent team to discuss your biosimilar marketing strategy.